Biocure Technology Inc. (BICTF)
- GlobeNewswire
Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the resulting entity will continue the business of Atriva Therapeutics. Shareholders of Atriva will receive not less than 75% of the securities of the resulting issuer, with the current shareholders of Biocure Technology holding the remainder. The transaction is subject to various terms and conditions, including
- Newsfile
Biocure Technology Inc. Enters into Exclusive Letter Agreement to Acquire Atriva Therapeutics GmbH in Reverse Takeover Transaction
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2023) - Biocure Technology Inc. (CSE: CURE) ("CURE" or the "Company") announces that it has entered into an exclusive letter agreement dated September 8, 2023 with Atriva Therapeutics GmbH. ("Atriva") whereby the Company will acquire all of the issued and outstanding securities of Atriva (the "Transaction"). The Transaction will be a business combination completed by way of a share exchange, share purchase, amalgamation, arrangement, t
